Want to see KLYG full AI Analyst Report?
KLYG Stock Chart & Stats
$0.15
<$0.01(4.82%)
At close: 4:00 PM EDT
$0.15
<$0.01(4.82%)
Day’s Range― - ―
52-Week Range$0.05 - $0.30
Previous CloseN/A
Volume21.70K
Average Volume (3M)23.14K
Market Cap
$6.52M
Enterprise Value$7.73
Total Cash (Recent Filing)$163.33K
Total Debt (Recent Filing)$384.66K
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding50,123,430
10 Day Avg. Volume41,753
30 Day Avg. Volume23,144
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)7.17
Price to Sales (P/S)1.91
P/FCF Ratio-30.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA very high gross margin (~76%) indicates durable pricing power or a favorable product mix in medical devices. That margin buffer supports reinvestment in R&D or commercial expansion, and helps absorb SG&A while the company scales toward sustained profitability.
Revenue Growth TrendMid-teens revenue growth over the trailing period signals underlying demand and expanding market adoption. Sustained top-line growth helps leverage fixed costs, improves operating leverage potential, and increases the probability of converting strong gross margins into lasting operating profits.
Improving Leverage And Balance-sheet StabilityReduced leverage and positive equity reflect strengthening financial flexibility. Lower debt-to-equity reduces solvency risk, supports capital allocation for product development or commercialization, and provides room to finance growth without immediate dilutive capital raises.
Bears Say
Ongoing Net Losses / Negative ROEPersistent net losses and a negative ROE indicate the company’s capital base is not yet producing returns. Until profitability is consistently achieved, the firm may need external funding, which can dilute shareholders and limit the ability to self-fund expansion or absorb shocks.
Volatile Cash Flow / Weak FCF TrendIrregular cash generation and a sharp decline in free cash flow growth versus prior periods undermine planning and investment capacity. Volatility raises the risk of periodic financing needs and makes it harder to rely on internal cash to fund commercialization or stabilize operations.
Small Operating ScaleA workforce of nine suggests limited internal capacity for sales, clinical, regulatory and manufacturing scale in a medical-device business. Small scale increases execution risk, reliance on partners or contractors, and could slow market penetration and product development timelines.
KLYG FAQ
What was Kelyniam Global Inc’s price range in the past 12 months?
Kelyniam Global Inc lowest stock price was $0.05 and its highest was $0.30 in the past 12 months.
What is Kelyniam Global Inc’s market cap?
Kelyniam Global Inc’s market cap is $6.52M.
When is Kelyniam Global Inc’s upcoming earnings report date?
Kelyniam Global Inc’s upcoming earnings report date is Aug 17, 2026 which is in 15 days.
How were Kelyniam Global Inc’s earnings last quarter?
Kelyniam Global Inc released its earnings results on May 19, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kelyniam Global Inc overvalued?
According to Wall Street analysts Kelyniam Global Inc’s price is currently Overvalued.
Does Kelyniam Global Inc pay dividends?
Kelyniam Global Inc does not currently pay dividends.
What is Kelyniam Global Inc’s EPS estimate?
Kelyniam Global Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kelyniam Global Inc have?
Kelyniam Global Inc has 50,123,430 shares outstanding.
What happened to Kelyniam Global Inc’s price movement after its last earnings report?
Kelyniam Global Inc reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.571%.
Which hedge fund is a major shareholder of Kelyniam Global Inc?
Currently, no hedge funds are holding shares in KLYG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kelyniam Global Inc
Kelyniam Global, Inc. operates as a medical device manufacturer, providing specialized solutions for patients. The company creates custom prosthetics using computer-aided design (CAD) and manufacturing (CAM) processes, employing advanced medical-grade polymers. Additionally, Kelyniam develops, produces, and supplies specific cranial and craniofacial fixation screws, crucial for the reconstruction of skull and facial structures. Its clientele encompasses health systems, hospitals, sales representatives, surgeons, insurance providers (payors), and individual patients. Established in 2005, the company was originally named Ketner Global Investments, Inc., rebranding to Kelyniam Global, Inc. in December 2007. Kelyniam Global is based in Collinsville, Connecticut.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors